Increased time spent on discussing testing for colorectal cancer (CRC) was associated with patient satisfaction in older adults. Adults aged 76 to 85 years were more likely to continue testing for ...

Multigene panel testing should be considered for all patients with colorectal cancer (CRC) who are diagnosed younger than age 50 years, new findings suggest. Among 450 patients with early-onset CRC, ...

WASHINGTON -- A blood-based test for the early detection of colorectal cancer (CRC) met its prespecified sensitivity and specificity endpoints, according to results from the PREEMPT CRC study. Using ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Multimodal circulating tumor DNA blood-based colorectal cancer screening tests may have clinically ...

Results from a new JAMA Network study support the large-scale use of FIT tests. The findings show that those who complete one or more fecal immunochemical test (FIT) screenings are associated with a ...

Dr Kristen Ciombor discusses utilization of biomarkers and molecular testing in the treatment of patients with CRC. Kristen Ciombor, MD: In terms of molecular testing for colorectal cancer, in early ...

Favoring blood-based colorectal cancer tests over stool-based CRC screening could lead to higher costs and worse outcomes for patients, according to a recent study published in JAMA Network Open. The ...

The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...

Please provide your email address to receive an email when new articles are posted on . At 12 months, 39% of those in the intervention group and 29% in the comparator group completed CRC screening.

Testing for mismatch repair (MMR) and microsatellite instability (MSI) among patients with colorectal cancer (CRC) increased from 22.7% in 2012 to 71.5% in 2021, but variations in access remain, with ...

New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...